Journal Watch · Frontiers in Immunology · 2026
Efficacy and safety of transarterial chemoembolization plus donafenib with or without camrelizumab for unresectable hepatocellular carcinoma: a propensity score matching analysis.
Although the TACE+D+C group exhibited immune-related adverse events (irAEs) (e.g., hypothyroidism and reactive cutaneous capillary endothelial proliferation), no significant differences were observed between the two groups in drug-related TRAEs, TRAEs after TACE, or Grade 3 TRAEs.<h4>Conclusion</h4>The TACE+D+C group significantly improves ORR, PFS and OS in uHCC patients with a comparable safety profile to the TACE+D group, while the single-center retrospective design limits generalizability, warranting prospective studies.
TL;DR
Although the TACE+D+C group exhibited immune-related adverse events (irAEs) (e.g., hypothyroidism and reactive cutaneous capillary endothelial proliferation), no significant differences were observed between the two groups in drug-related TRAEs, TRAEs after TACE, or Grade 3 TRAEs.<h4>Conclusion</h4>The TACE+D+C group significantly improves ORR, PFS and OS in uHCC patients with a comparable safety profile to the TACE+D group, while the single-center retrospective design limits generalizability, warranting prospective studies.
Key findings
- Multivariable Cox regression identified Barcelona Clinic Liver Cancer (BCLC) stage (hazard ratio [HR] = 1.69, <i>P</i> = 0.029), Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) (HR = 3.66, <i>P</i> < 0.001), and alpha-fetoprotein (AFP) level (HR = 2.38, <i>P</i> < 0.001) as independent prognostic factors for OS.
- For PFS, independent prognostic factors were PIVKA-II (HR = 3.07, <i>P</i> < 0.001) and AFP level (HR = 2.52, <i>P</i> < 0.001).
- Although the TACE+D+C group exhibited immune-related adverse events (irAEs) (e.g., hypothyroidism and reactive cutaneous capillary endothelial proliferation), no significant differences were observed between the two groups in drug-related TRAEs, TRAEs after TACE, or Grade 3 TRAEs.<h4>Conclusion</h4>The TACE+D+C group significantly improves ORR, PFS and OS in uHCC patients with a comparable safety profile to the TACE+D group, while the single-center retrospective design limits generalizability, warranting prospective studies.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Compared with the TACE+D group, the TACE+D+C group demonstrated a significantly higher partial response (PR) (37.93% vs 20.69%, <i>P</i> = 0.041), objective response rate (ORR) (62.07% vs 36.21%, <i>P</i> = 0.005) and disease control rate (DCR) (86.21% vs 70.69%, <i>P</i> = 0.042). Notably, the TACE+D+C group achieved a remarkably longer mOS than the TACE+D group (23.1 months vs 12.0 months, <i>P</i> = 0.022). Similarly, median PFS was significantly prolonged in the TACE+D+C group compared with the TACE+D group (13.0 months vs 7.8 months, <i>P</i> = 0.007).
Full abstract (original)
Background: <h4>Purpose</h4>To compare the efficacy and safety of transarterial chemoembolization plus donafenib (TACE+D) and TACE plus donafenib combined with camrelizumab (TACE+D+C) in unresectable hepatocellular carcinoma (uHCC), using propensity score matching (PSM) to minimize selection bias.<h4>Methods</h4>A single-center retrospective study analyzed 278 patients with uHCC who received treatment between 2021 and 2024, and they were divided into TACE+D and TACE+D+C groups. PSM was used to perform 1:1 matching (58 patients per group). Tumor response, progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs) were compared; Cox regression was used to identify prognostic factors.<h4>Results</h4>After PSM, 58 patients were included in each group.
What they did: Compared with the TACE+D group, the TACE+D+C group demonstrated a significantly higher partial response (PR) (37.93% vs 20.69%, <i>P</i> = 0.041), objective response rate (ORR) (62.07% vs 36.21%, <i>P</i> = 0.005) and disease control rate (DCR) (86.21% vs 70.69%, <i>P</i> = 0.042). Notably, the TACE+D+C group achieved a remarkably longer mOS than the TACE+D group (23.1 months vs 12.0 months, <i>P</i> = 0.022). Similarly, median PFS was significantly prolonged in the TACE+D+C group compared with the TACE+D group (13.0 months vs 7.8 months, <i>P</i> = 0.007).
Results & conclusions: Multivariable Cox regression identified Barcelona Clinic Liver Cancer (BCLC) stage (hazard ratio [HR] = 1.69, <i>P</i> = 0.029), Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) (HR = 3.66, <i>P</i> < 0.001), and alpha-fetoprotein (AFP) level (HR = 2.38, <i>P</i> < 0.001) as independent prognostic factors for OS. For PFS, independent prognostic factors were PIVKA-II (HR = 3.07, <i>P</i> < 0.001) and AFP level (HR = 2.52, <i>P</i> < 0.001). Although the TACE+D+C group exhibited immune-related adverse events (irAEs) (e.g., hypothyroidism and reactive cutaneous capillary endothelial proliferation), no significant differences were observed between the two groups in drug-related TRAEs, TRAEs after TACE, or Grade 3 TRAEs.<h4>Conclusion</h4>The TACE+D+C group significantly improves ORR, PFS and OS in uHCC patients with a comparable safety profile to the TACE+D group, while the single-center retrospective design limits generalizability, warranting prospective studies.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1694973 · PubMed 42079632.
Why it matters for pharma & biotech
- Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this Frontiers in Immunology study find?
Although the TACE+D+C group exhibited immune-related adverse events (irAEs) (e.g., hypothyroidism and reactive cutaneous capillary endothelial proliferation), no significant differences were observed between the two groups in drug-related TRAEs, TRAEs after TACE, or Grade 3 TRAEs.<h4>Conclusion</h4>The TACE+D+C group significantly improves ORR, PFS and OS in uHCC patients with a comparable safety profile to the TACE+D group, while the single-center retrospective design limits generalizability, warranting prospective studies.
What type of study is this?
It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. Compared with the TACE+D group, the TACE+D+C group demonstrated a significantly higher partial response (PR) (37.93% vs 20.69%, <i>P</i> = 0.041), objective response rate (ORR) (62.07% vs 36.21%, <i>P</i> = 0.005) and disease control rate (DCR) (86.21% vs 70.69%, <i>P</i> = 0.042).
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1694973. PubMed ID: 42079632. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/efficacy-and-safety-of-transarterial-chemoembolization-plus-donafenib-wi-694973/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides